Chicago, 29th May 2025 — Clearview Market Insights (CVMI) forecasts that the global microbiome sequencing services market will grow from USD 3.4 billion in 2024 to USD 12.6 billion by 2031, registering a compound annual growth rate (CAGR) of 20.5 percent. This explosive growth is supported by rapid adoption across pharmaceutical development, nutraceutical innovation, precision agriculture, environmental monitoring, and emerging consumer health products.
We are witnessing a shift from exploratory microbiome research to actionable diagnostics and commercial-scale applications," said Dr. Ravi Deshmukh, Senior Genomics Analyst at CVMI. "Microbiome sequencing services now directly impact clinical trials, regulatory submissions, soil health programs, and personalized nutrition platforms.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-microbiome-sequencing-services-market/
Key Figures
Metric | 2024 | 2031 | CAGR (2024–31) |
Market Value (USD Billion) | 3.4 | 12.6 | 20.5 % |
Human Health Applications | 42 % | 44 % | — |
16S rRNA Share | 38 % | 30 % | — |
Shotgun Metagenomics | 34 % | 40 % | — |
Long-Read Sequencing | 5 % | 12 % | — |
Top 5 Vendors’ Share | 67 % | 61 % | — |
Growth Drivers
- Precision Medicine & Drug Discovery – Biopharma players leverage microbiome profiling for immunotherapy response prediction, gut-brain axis targeting, and next-generation antibiotic development.
- Functional Foods & Personalized Nutrition – Wellness brands now routinely test gut microbiota to optimize prebiotic and probiotic formulations, moving toward consumer-specific dietary supplements.
- Agricultural Productivity – Soil microbiome sequencing helps optimize yield, control disease, and reduce chemical inputs through biologically driven farming.
- Environmental Surveillance – National monitoring programs use metagenomics to track water, soil, and urban microbiomes affected by climate stress and pollution.
- Cosmeceuticals and Dermatology – Skin microbiome studies enable evidence-based formulation of skincare, anti-aging, and dermo-probiotic products.
Company Highlights
Company | 2024 Market Share | Strategic Focus |
Illumina | 28 % | Microbiome-specific library prep kits and end-to-end sequencing bundles |
Zymo Research | 12 % | Extraction and prep kits; turnkey sequencing workflows |
CosmosID | 10 % | Curated metagenomics and AI-driven pathogen detection tools |
Eurofins Genomics | 9 % | Sample logistics and regulatory-compliant sequencing for food, pharma, and environment |
Novogene | 8 % | High-throughput agricultural and multi-omics pipelines |
Regional Insights
- North America – Home to NIH Microbiome projects, pharma partnerships, and the booming consumer microbiome testing industry. Holds 42% market share.
- Europe – Strong public funding, microbiome start-ups, and cross-border research collaborations. Key centers include Germany, France, and the Netherlands.
- Asia-Pacific – Fastest growing at 24.2% CAGR, led by China and India’s national microbiome initiatives and growing soil/agriculture applications.
- Latin America – High microbiome use in precision agriculture and livestock optimization. Brazil leads with national soil health data infrastructure.
- Middle East & Africa – Nascent markets with increasing interest in climate-resilient agriculture and water-quality metagenomics.
2024–25 Milestones
Quarter | Event | Outcome |
Q1 2024 | Illumina released NovaSeq Microbiome Plus kit | Reduced error rates in low-biomass samples by 20% |
Q2 2024 | CosmosID launched AMR-enhanced metagenomic pipeline | Clinical labs cut annotation time by 35% |
Q3 2024 | Zymo introduced portable extraction kits | Field researchers in India and Brazil scaled soil microbiome sampling |
Q4 2024 | Novogene doubled throughput with HiSeq-X integration | Shortened turnaround to 48 hours for high-volume agricultural studies |
Q1 2025 | GutBiomeX debuted AI-powered FMT donor matching | Clinical trials initiated in Canada and Germany |
Technology Trends
- Long-Read Sequencing Growth – Accuracy and completeness of rare and novel microbial genomes improve functional annotation and clinical insights.
- AI-Augmented Annotation – Taxonomic classification time cut by over 40%; enables automation and real-time interpretation.
- Multi-Omics Integration – Combination of metagenomics with metabolomics and proteomics enhances understanding of microbiota-host interactions.
- Blockchain-Backed Microbiome Data – Improves consent traceability, access rights, and commercial use licensing for personal and clinical datasets.
- In-Field Sequencing Kits – Used in agriculture and conservation; allow real-time microbial monitoring for yield prediction and ecosystem health.
Strategic Roadmap to 2031
- 2025 – Personalized gut microbiome reports integrated into consumer apps and dietary recommendations.
- 2026 – AI-generated microbiome taxonomies become standard in food and pharma validation.
- 2027 – Sequencing cost per sample falls below USD 10, accelerating mass adoption.
- 2028 – Multi-omics diagnostics receive first FDA and EMA approval.
- 2029 – Global harmonization on DTC testing guidelines in microbiome field.
- 2030 – Regenerative farming policies mandate soil microbiome certification.
- 2031 – Human microbiome data included in electronic health records in leading OECD nations.
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
